Rocket Pharmaceuticals, Inc. RCKT 深 滬
等待開盤 11-04 09:30:00 美东时间
2.51
+0.040
+1.62%
華盛通- 最 高2.635
- 今 開2.49
- 成交量 128.68万股
- 最 低 2.42
- 昨 收 2.47
- 總市值 2.76亿
- 52周最高 5.45
- 市盈率 靜 --
- 換手率 1.17%
- 52周最低 2.165
- 委 比 -21.95%
- 總股本 1.10亿
- 歷史最高 67.48
- 量 比 0.74
- 振 幅 8.70%
- 歷史最低 2.165
- 每 手 1
- 風險率 0.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer
Syndax Pharmaceuticals announced the retirement of CFO Keith A. Goldan and the appointment of Aaron A. Ondrey as the new CFO. Goldan, who played a key role in the successful launches of Revuforj and Niktimvo, will remain with the company through year-end to support the transition. Ondrey brings over 25 years of financial and operational leadership experience in the biotechnology industry.
11-02 21:01
美股大行评级 | 潜在涨幅179.23%！奥本海默上调Aurora Innovation目标价至16美元，维持"跑赢大市"评级
今日重点评级关注：奥本海默：维持Aurora Innovation"跑赢大市"评级，目标价从15美元升至16美元；富国银行：维持Applied Digital"超配"评级，目标价从50美元升至55美元
10-09 16:25
This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Goldman Sachs analyst Richard Law upgraded Rocket Pharmaceuticals Inc (NASDAQ:RCKT) from Sell to ...
10-08 20:29
美股大行评级 | 潜在涨幅175.74%！美光科技获DA Davidson上调目标价至3000美元，维持"买入"评级
今日重点评级关注：DA Davidson：维持美光科技"买入"评级，目标价从2100美元升至3000美元；Leerink Partners：维持OmniAb"跑赢大市"评级，目标价从10美元升至12美元
10-08 12:30
Leerink Partners Maintains Market Perform on Rocket Pharmaceuticals, Lowers Price Target to $4
Leerink Partners analyst Roanna Ruiz maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Market Perform and lowers the price target from $7 to $4.
10-08 01:01
Rocket Pharma updates progress on RP-A501 for Danon disease
Rocket Pharmaceuticals (RCKT) said that it has a clear path to complete a pivotal phase 2 trial for its Danon disease asset, RP-A501. The company said 12 male patients will receive treatment. Co-prim...
10-07 23:44
Rocket Pharmaceuticals Secures Hercules Loan to Extend Runway
Rocket Pharmaceuticals ( ($RCKT) ) has issued an update. On September 30, 2026,...
10-07 05:54
美股大行评级 | 矿业股获齐声唱多！金田、纽曼矿业等目标价均获上调；携程遭看淡至60美元，较现价仍溢价5成
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从10.25美元升至11美元；Needham：上调Rocket Pharmaceuticals"买入"评级，目标价9美元
09-17 16:16
Rocket Pharmaceuticals Aligned With FDA on Continued Enrollment and Dosing and key elements of Phase 2 trial of RP-A501 for Danon disease
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced alignment with the U.S. Food and Drug Administration (FDA) on cont...
09-15 19:12
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
